Sun Pharmaceutical is leveraging a US generics pricing recovery while building a higher-margin specialty pipeline in dermatology and ophthalmology. India branded formulations continue to grow steadily, providing a stable cash base. Specialty launch cadence and FDA inspection outcomes are the key signal drivers.
Thesis reviewed May 29, 2026
Sun Pharmaceutical Industries Ltd. (ADR) is headquartered in India, which is currently showing moderate signals.
🇮🇳India52AVOIDView India risk detail →💊Pharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| AZN | AstraZeneca PLC | 50 | +11% | ↓0% | EARLY |
| JNJ | Johnson & Johnson | 50 | +8% | ↓0% | NEUTRAL |
| REGN | Regeneron Pharmaceuticals Inc. | 50 | -16% | ↓0% | AVOID |
| TAK | Takeda Pharmaceutical Company Limited | 50 | +10% | ↓0% | NEUTRAL |
| LLY | Eli Lilly and Company | 50 | +24% | ↓0% | EARLY |
| PFE | Pfizer Inc. | 50 | +6% | ↓0% | NEUTRAL |
| NVO | Novo Nordisk A/S | 50 | +15% | ↓0% | EARLY |
Investors who hold SUNPY may also have indirect exposure through these country funds.
US generic drug pricing stabilizes, lifting India pharma margins
Sun Pharma specialty dermatology pipeline advances